Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kurosu, Tetsuya ^a   Nagao, Toshikage ^a   Wu, Nan ^a   Oshikawa, Gaku ^a   Miura, Osamu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL LINE; ETOPOSIDE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; FUSION PROTEINS, BCR-ABL; GLYCOGEN SYNTHASE KINASE 3; IMMUNOBLOTTING; IMMUNOPRECIPITATION; JANUS KINASE 2; MICE; NOCODAZOLE; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES;

EID: 84894176589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079478     Document Type: Article

References (40)

1. Goldman JM, Melo JV (2003) Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464. (Pubitemid 37211061)
2. Wong S, Witte ON (2004) The BCR-ABL Story: Bench to Bedside and Back. Annu Rev Immunol 22: 247-306. (Pubitemid 38680424)
3. Ihle JN, Gilliland DG (2007) Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17: 8-14. (Pubitemid 46109298)
4. Levine RL, Pardanani A, Tefferi A, Gilliland DG (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7: 673-683. (Pubitemid 47327415)
5. Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15: 4263-4269.
6. Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116: 5089-5102.
7. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10: 127-140.
8. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12: 513-526.
9. Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, et al. (2011) Role of tyrosine kinase inhibitors in the management of Philadelphia chromosomepositive acute lymphoblastic leukemia. Curr Hematol Malig Rep 6: 187-194.
10. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164. (Pubitemid 34161136)
11. Medema RH, Macurek L (2012) Checkpoint control and cancer. Oncogene 31: 2601-2613.
12. Maugeri-Sacca M, Bartucci M, De Maria R (2013) Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev 39: 525-533.
13. Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O (2005) Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene 24: 1973-1981. (Pubitemid 40516192)
14. Klucher KM, Lopez DV, Daley GQ (1998) Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91: 3927-3934. (Pubitemid 28225762)
15. Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, et al. (2007) Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Oncogene 26: 2975-2987. (Pubitemid 46733650)
16. Nagao T, Oshikawa G, Wu N, Kurosu T, Miura O (2011) DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3beta. PLoS One 6: e27397.
17. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O (2009) Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res 69: 3927-3936.
18. Oshikawa G, Nagao T, Wu N, Kurosu T, Miura O (2011) c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J Biol Chem 286: 30263-30273.
19. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG (2003) FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17: 120-124. (Pubitemid 36175896)
20. Morita S, Kojima T, Kitamura T (2000) Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7: 1063-1066. (Pubitemid 30398356)
21. Witherington J, Bordas V, Haigh D, Hickey DM, Ife RJ, et al. (2003) 5-arylpyrazolo[ 3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett 13: 1581-1584. (Pubitemid 36428565)
22. Miura O, Cleveland JL, Ihle JN (1993) Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol 13: 1788-1795. (Pubitemid 23068117)
23. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, et al. (2000) The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 275: 14466-14475. (Pubitemid 30339733)
24. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, et al. (2007) The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 92: 27-34. (Pubitemid 46232655)
25. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, et al. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 8: 1725-1738.
26. Workman P, Clarke PA, Raynaud FI, van Montfort RL (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70: 2146-2157.
27. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, et al. (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688-4695.
28. Xu N, Lao Y, Zhang Y, Gillespie DA (2012) Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012: 951724.
29. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J (2010) Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 21: 683-691.
30. Henry MK, Lynch JT, Eapen AK, Quelle FW (2001) DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 98: 834-841.
31. Nimbalkar D, Quelle FW (2008) Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. Cell Cycle 7: 2877-2885.
32. King FW, Skeen J, Hay N, Shtivelman E (2004) Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 3: 634-637. (Pubitemid 40278209)
33. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, et al. (2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7: 193-204. (Pubitemid 40248344)
34. Tonic I, Yu WN, Park Y, Chen CC, Hay N (2010) Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. J Biol Chem 285: 23790-23798.
35. Xu N, Hegarat N, Black EJ, Scott MT, Hochegger H, et al. (2010) Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol 190: 297-305.
36. Li P, Goto H, Kasahara K, Matsuyama M, Wang Z, et al. (2012) P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol Biol Cell 23: 1582-1592.
37. Ray-David H, Romeo Y, Lavoie G, Deleris P, Tcherkezian J, et al. (2013) RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance. Oncogene in press.
38. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, et al. (2007) The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 67: 6574-6581. (Pubitemid 47105501)
39. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, et al. (2012) Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res 18: 6723-6731.
40. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437. (Pubitemid 46698720)